Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
VALENCIA, Calif., Feb. 26, 2016 -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) today announced that it anticipates being unable to timely file its Annual Report on Form 10-K for the year ended December 31, 2015 by the filing deadline on February 29, 2016. In such event, the Company anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission (SEC).
The Company is experiencing delays in completing its analysis of accounting issues resulting from the previously announced termination of the Sanofi License Agreement, and expects that additional time will be needed to complete a detailed review of the impairment of assets as a consequence of the termination.
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding future filings with the SEC. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, developments related to the ongoing analysis of accounting issues arising from the termination of the Sanofi License Agreement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release except as required by law.
Company Contact: Matthew Pfeffer Chief Executive Officer (661) 775-5300 [email protected]
